Portuguese 
Spanish 
Discover Eurofarma’s semaglutide pens, medications that arrive at Brazilian pharmacies with more competitive prices through the EuroCuida program.
Eurofarma has started national sales of its semaglutide pens and has increased competition in the Brazilian market for medications used in the treatment of obesity, overweight, and type 2 diabetes.
The products Poviztra and Extensior arrive at pharmacies with more competitive prices than well-known brands like Ozempic and Wegovy. The strategy is part of EuroCuida, a patient support program created by the pharmaceutical company to offer differentiated commercial conditions to registered individuals.
The new phase does not change the need for a medical prescription and places the Brazilian company in direct competition for one of the most active segments of the pharmaceutical industry. Eurofarma announced the price reduction in June 2026, starting at the beginning of July of the same year.
-
In 2005, a 21-year-old British student raised over a million dollars by selling a million pixels on a webpage for one dollar each.
-
Adopted Cat’s Unusual Paws Tie Guinness World Record Unbroken Since 2002
-
Philosophy Professor’s DIY Phone Grip Solution Becomes Multi-Million Selling Product and Company
-
15-year-old Brazilian builds batteries, generators, and a community radio from scrap, becomes youngest guest at MIT’s historic program
Discover Eurofarma’s pens
The Poviztra and Extensior pens use semaglutide, an active ingredient associated with injectable medications for the treatment of chronic diseases. Poviztra is for patients with obesity and overweight, while Extensior is for people with type 2 diabetes.
According to Eurofarma, the initial price of Poviztra starts at R$ 295 for the initial doses. The continuation of the treatment can start at R$ 309, according to the EuroCuida rules and the conditions applied to the registered patient.
The company reported that the reduction can reach 48% in some presentations. With this, the Brazilian versions compete with medications that have gained popularity in the country, especially Ozempic and Wegovy, both linked to the semaglutide market.
How the reduced price through EuroCuida works
The discount on Eurofarma’s pens occurs within EuroCuida, the pharmaceutical company’s own patient support program. To access the reduced prices, the consumer needs to register and follow the conditions established by the company.
The measure aims to increase the competitiveness of the medications in the national pharmaceutical retail. In practice, the company tries to position Poviztra and Extensior as more accessible alternatives within a market that has grown rapidly in recent years.
The discounted pens were already available in pharmacies on July 1, 2026. The move reinforces Eurofarma’s presence in a sector dominated by high-demand and high-value products on the shelves.
Why the Arrival of the Pens Draws Attention
The national sale of pens with semaglutide draws attention because it occurs at a time of strong demand for medications for obesity, overweight, and type 2 diabetes. The topic has gained space in pharmacies, medical offices, and online searches.
Even with reduced prices, Poviztra and Extensior require professional guidance. A doctor needs to prescribe the treatment, considering the patient’s history, the correct dosage, and the possible effects related to the use of semaglutide.
The arrival of Eurofarma’s medications, therefore, marks a new phase of competition in Brazil. What was once dominated by international names now includes cheaper Brazilian versions, registered in the EuroCuida program and aimed at patients who require continuous monitoring.
